A 2026 Drosophila Parkinson’s model exposed male and female flies to 500 μM rotenone. By 60 days, male flies had worse survival/climbing than female flies; the paper is a vulnerability screen, not evidence that the same genes are ready human biomarkers.1 Research Highlights 500 μM rotenone split male and female flies: Iyer et al. used …
A 2026 Parkinson’s disease study used gene-expression data and genome-scale metabolic modeling to predict patient-level metabolite patterns, then separated 104 patients into 3 metabolic subgroups that were partly reproduced in an independent 81-patient validation dataset. Research Highlights Patient-level modeling found heterogeneity: Abdik et al. predicted secretion tendencies for 802 analyzable metabolites across 104 postmortem substantia …
A 2026 mouse and cell study found that ATP11B loss pushed aged brains toward hippocampal iron accumulation, mitochondrial dysfunction, neuronal ferroptosis, and worse memory behavior than wild-type comparison mice; ATP11B overexpression then improved multiple learning and memory tests in 18-month-old mice. Research Highlights Memory signal: ATP11B-deficient mice performed worse than wild-type mice on Morris water …
A 2026 medRxiv preprint found that REDDI, a resting-state magnetoencephalography machine-learning pipeline, separated mild cognitive impairment, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis with 0.81 ± 0.04 balanced accuracy across 5 folds.1 That is a meaningful jump over the prior 67.1% MEG benchmark, but it is still research-stage decision support rather than a clinical …
A 2026 Parkinsonism study involving 63 male rats found that Antrodia cinnamomea plus citrate-stabilized silver nanoparticles reduced 6-OHDA motor, oxidative-stress, inflammatory, α-synuclein, and apoptosis markers, while dopamine and acetylcholine recovery remained nonsignificant. The useful claim is a multitarget preclinical signal, not a Parkinson’s disease treatment recommendation. Research Highlights Combination treatment looked strongest: Tekiner et al. …
A 2026 ALZAN memory-clinic cohort found that cerebrospinal-fluid alpha-synuclein seed amplification assay detected 19 of 20 Lewy body dementia cases, with 95% sensitivity and 93.5% specificity against non-Lewy-body, non-Alzheimer’s controls.1 The same assay was positive in 32 of 203 Alzheimer’s disease patients, which makes the result a co-pathology warning as much as a diagnostic win. …
In 433 non-demented amyotrophic lateral sclerosis (ALS) patients, clinically significant anxiety was present in 18.2% for state anxiety and 13.9% for trait anxiety. The strongest predictor was not motor severity, cognition, or caregiver-rated behavior; it was depression, especially cognitive-affective depression symptoms.1 Research Highlights ALS anxiety was measurable but not universal: Aiello et al. found clinically …